Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

As we mark Lung Cancer Awareness Month, it is a time to acknowledge that screening and prevention are vital, and equally crucial is ensuring that patients have access to state-of-the-art care and research. Herein, I spotlight some of the transformative work underway at City of Hope.

November 07, 2025

Vol.51 No.41

By Ravi Salgia

Cancer Policy

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

FDA announced six additional awardees under the Commissioner’s National Priority Voucher pilot program, which aims to accelerate review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, Oct. 24, June 20, 2025).

Enhancing the body’s “first responder” cells may boost immune therapy, Mayo study finds

Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using distinct approaches, found that “first-responder” immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells.

October 31, 2025

Vol.51 No.40

Drugs & Targets

EC approves Keytruda combination for a head-and-neck indication

The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1.

October 31, 2025

Vol.51 No.40

In Brief

Korman, Regev, and Rathmell awarded Cancer Research Institute honors in cancer immunotherapy

Alan KormanAviv RegevJeffrey C. RathmellThe Cancer Research Institute has announced the 2025 recipients of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology and the Frederick W. Alt Award for New Discoveries in Immunology.

October 24, 2025

Vol.51 No.39

Clinical Roundup

Zanzalintinib + atezolizumab improve survival in advanced CRC

Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.

October 24, 2025

Vol.51 No.39

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

YOU MAY BE INTERESTED IN

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

Enhancing the body’s “first responder” cells may boost immune therapy, Mayo study finds

EC approves Keytruda combination for a head-and-neck indication

Korman, Regev, and Rathmell awarded Cancer Research Institute honors in cancer immunotherapy

Zanzalintinib + atezolizumab improve survival in advanced CRC

Renew today!

Subscriber content

Never miss an issue!

Login